
Onychomycosis (Tinea Unguium) Drug Industry Research Report 2024
Description
Onychomycosis (Tinea Unguium) Drug Industry Research Report 2024
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.
Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.
Highlights
The global Onychomycosis (Tinea Unguium) Drug market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2025 and 2030.
Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.
North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.
In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Onychomycosis (Tinea Unguium) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Onychomycosis (Tinea Unguium) Drug.
The Onychomycosis (Tinea Unguium) Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Onychomycosis (Tinea Unguium) Drug market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Onychomycosis (Tinea Unguium) Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Pfizer
Yangtze River
Torrent Pharma
J&J
Chengdu Brilliant
Novartis
Qilu Pharmaceutical
Xiuzheng Pharmaceutical
Hubei Hengan
TARO
Perrigo
Galderma pharm
Zhejiang Deyer
Valeant Pharma
Moberg
Product Type Insights
Global markets are presented by Onychomycosis (Tinea Unguium) Drug type, along with growth forecasts through 2030. Estimates on revenue are based on the price in the supply chain at which the Onychomycosis (Tinea Unguium) Drug are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
Onychomycosis (Tinea Unguium) Drug segment by Type
Oral Medication
External Medicine
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the Onychomycosis (Tinea Unguium) Drug market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Onychomycosis (Tinea Unguium) Drug market.
Onychomycosis (Tinea Unguium) Drug Segment by Application
Age under 18
Age 18-50
Age above 50
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2019-2030.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Onychomycosis (Tinea Unguium) Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Onychomycosis (Tinea Unguium) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Onychomycosis (Tinea Unguium) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Onychomycosis (Tinea Unguium) Drug industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Onychomycosis (Tinea Unguium) Drug.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Onychomycosis (Tinea Unguium) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
95 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Onychomycosis (Tinea Unguium) Drug by Type
- 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
- 1.2.2 Oral Medication
- 1.2.3 External Medicine
- 2.3 Onychomycosis (Tinea Unguium) Drug by Application
- 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
- 2.3.2 Age under 18
- 2.3.3 Age 18-50
- 2.3.4 Age above 50
- 2.4 Assumptions and Limitations
- 3 Onychomycosis (Tinea Unguium) Drug Breakdown Data by Type
- 3.1 Global Onychomycosis (Tinea Unguium) Drug Historic Market Size by Type (2019-2024)
- 3.2 Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Type (2025-2030)
- 4 Onychomycosis (Tinea Unguium) Drug Breakdown Data by Application
- 4.1 Global Onychomycosis (Tinea Unguium) Drug Historic Market Size by Application (2019-2024)
- 4.2 Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Application (2019-2024)
- 5 Global Growth Trends
- 5.1 Global Onychomycosis (Tinea Unguium) Drug Market Perspective (2019-2030)
- 5.2 Global Onychomycosis (Tinea Unguium) Drug Growth Trends by Region
- 5.2.1 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region: 2019 VS 2023 VS 2030
- 5.2.2 Onychomycosis (Tinea Unguium) Drug Historic Market Size by Region (2019-2024)
- 5.2.3 Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Region (2025-2030)
- 5.3 Onychomycosis (Tinea Unguium) Drug Market Dynamics
- 5.3.1 Onychomycosis (Tinea Unguium) Drug Industry Trends
- 5.3.2 Onychomycosis (Tinea Unguium) Drug Market Drivers
- 5.3.3 Onychomycosis (Tinea Unguium) Drug Market Challenges
- 5.3.4 Onychomycosis (Tinea Unguium) Drug Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Onychomycosis (Tinea Unguium) Drug Players by Revenue
- 6.1.1 Global Top Onychomycosis (Tinea Unguium) Drug Players by Revenue (2019-2024)
- 6.1.2 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Players (2019-2024)
- 6.2 Global Onychomycosis (Tinea Unguium) Drug Industry Players Ranking, 2022 VS 2023 VS 2024
- 6.3 Global Key Players of Onychomycosis (Tinea Unguium) Drug Head office and Area Served
- 6.4 Global Onychomycosis (Tinea Unguium) Drug Players, Product Type & Application
- 6.5 Global Onychomycosis (Tinea Unguium) Drug Players, Date of Enter into This Industry
- 6.6 Global Onychomycosis (Tinea Unguium) Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Onychomycosis (Tinea Unguium) Drug Market Size (2019-2030)
- 7.2 North America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 7.3 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024)
- 7.4 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030)
- 7.5 United States
- 7.6 Canada
- 8 Europe
- 8.1 Europe Onychomycosis (Tinea Unguium) Drug Market Size (2019-2030)
- 8.2 Europe Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 8.3 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024)
- 8.4 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030)
- 7.4 Germany
- 7.5 France
- 7.6 U.K.
- 7.7 Italy
- 7.8 Russia
- 7.9 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size (2019-2030)
- 9.2 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 9.3 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024)
- 9.4 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030)
- 8.4 China
- 8.5 Japan
- 8.6 South Korea
- 8.7 Southeast Asia
- 8.8 India
- 8.9 Australia
- 10 Latin America
- 10.1 Latin America Onychomycosis (Tinea Unguium) Drug Market Size (2019-2030)
- 10.2 Latin America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 10.3 Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024)
- 10.4 Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030)
- 9.4 Mexico
- 9.5 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size (2019-2030)
- 11.2 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 11.3 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024)
- 11.4 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030)
- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 UAE
- 12 Players Profiled
- 11.1 Pfizer
- 11.1.1 Pfizer Company Detail
- 11.1.2 Pfizer Business Overview
- 11.1.3 Pfizer Onychomycosis (Tinea Unguium) Drug Introduction
- 11.1.4 Pfizer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.1.5 Pfizer Recent Development
- 11.2 Yangtze River
- 11.2.1 Yangtze River Company Detail
- 11.2.2 Yangtze River Business Overview
- 11.2.3 Yangtze River Onychomycosis (Tinea Unguium) Drug Introduction
- 11.2.4 Yangtze River Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.2.5 Yangtze River Recent Development
- 11.3 Torrent Pharma
- 11.3.1 Torrent Pharma Company Detail
- 11.3.2 Torrent Pharma Business Overview
- 11.3.3 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Introduction
- 11.3.4 Torrent Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.3.5 Torrent Pharma Recent Development
- 11.4 J&J
- 11.4.1 J&J Company Detail
- 11.4.2 J&J Business Overview
- 11.4.3 J&J Onychomycosis (Tinea Unguium) Drug Introduction
- 11.4.4 J&J Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.4.5 J&J Recent Development
- 11.5 Chengdu Brilliant
- 11.5.1 Chengdu Brilliant Company Detail
- 11.5.2 Chengdu Brilliant Business Overview
- 11.5.3 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Introduction
- 11.5.4 Chengdu Brilliant Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.5.5 Chengdu Brilliant Recent Development
- 11.6 Novartis
- 11.6.1 Novartis Company Detail
- 11.6.2 Novartis Business Overview
- 11.6.3 Novartis Onychomycosis (Tinea Unguium) Drug Introduction
- 11.6.4 Novartis Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.6.5 Novartis Recent Development
- 11.7 Qilu Pharmaceutical
- 11.7.1 Qilu Pharmaceutical Company Detail
- 11.7.2 Qilu Pharmaceutical Business Overview
- 11.7.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Introduction
- 11.7.4 Qilu Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.7.5 Qilu Pharmaceutical Recent Development
- 11.8 Xiuzheng Pharmaceutical
- 11.8.1 Xiuzheng Pharmaceutical Company Detail
- 11.8.2 Xiuzheng Pharmaceutical Business Overview
- 11.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Introduction
- 11.8.4 Xiuzheng Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.8.5 Xiuzheng Pharmaceutical Recent Development
- 11.9 Hubei Hengan
- 11.9.1 Hubei Hengan Company Detail
- 11.9.2 Hubei Hengan Business Overview
- 11.9.3 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Introduction
- 11.9.4 Hubei Hengan Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.9.5 Hubei Hengan Recent Development
- 11.10 TARO
- 11.10.1 TARO Company Detail
- 11.10.2 TARO Business Overview
- 11.10.3 TARO Onychomycosis (Tinea Unguium) Drug Introduction
- 11.10.4 TARO Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.10.5 TARO Recent Development
- 11.11 Perrigo
- 11.11.1 Perrigo Company Detail
- 11.11.2 Perrigo Business Overview
- 11.11.3 Perrigo Onychomycosis (Tinea Unguium) Drug Introduction
- 11.11.4 Perrigo Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.11.5 Perrigo Recent Development
- 11.12 Galderma pharm
- 11.12.1 Galderma pharm Company Detail
- 11.12.2 Galderma pharm Business Overview
- 11.12.3 Galderma pharm Onychomycosis (Tinea Unguium) Drug Introduction
- 11.12.4 Galderma pharm Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.12.5 Galderma pharm Recent Development
- 11.13 Zhejiang Deyer
- 11.13.1 Zhejiang Deyer Company Detail
- 11.13.2 Zhejiang Deyer Business Overview
- 11.13.3 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Introduction
- 11.13.4 Zhejiang Deyer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.13.5 Zhejiang Deyer Recent Development
- 11.14 Valeant Pharma
- 11.14.1 Valeant Pharma Company Detail
- 11.14.2 Valeant Pharma Business Overview
- 11.14.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Introduction
- 11.14.4 Valeant Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.14.5 Valeant Pharma Recent Development
- 11.15 Moberg
- 11.15.1 Moberg Company Detail
- 11.15.2 Moberg Business Overview
- 11.15.3 Moberg Onychomycosis (Tinea Unguium) Drug Introduction
- 11.15.4 Moberg Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022)
- 11.15.5 Moberg Recent Development
- 13 Report Conclusion
- 14 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
- Table 4. Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
- Table 5. Global Onychomycosis (Tinea Unguium) Drug Market Size by Type (2019-2024) & (US$ Million)
- Table 6. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2019-2024)
- Table 7. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
- Table 8. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2025-2030)
- Table 9. Global Onychomycosis (Tinea Unguium) Drug Market Size by Application (2019-2024) & (US$ Million)
- Table 10. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2019-2024)
- Table 11. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
- Table 12. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2025-2030)
- Table 13. Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
- Table 14. Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (2019-2024) & (US$ Million)
- Table 15. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region (2019-2024)
- Table 16. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
- Table 17. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region (2025-2030)
- Table 18. Onychomycosis (Tinea Unguium) Drug Market Trends
- Table 19. Onychomycosis (Tinea Unguium) Drug Market Drivers
- Table 20. Onychomycosis (Tinea Unguium) Drug Market Challenges
- Table 21. Onychomycosis (Tinea Unguium) Drug Market Restraints
- Table 22. Global Top Onychomycosis (Tinea Unguium) Drug Manufacturers by Revenue (US$ Million) & (2019-2024)
- Table 23. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Manufacturers (2019-2024)
- Table 24. Global Onychomycosis (Tinea Unguium) Drug Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
- Table 25. Global Key Players of Onychomycosis (Tinea Unguium) Drug, Headquarters and Area Served
- Table 26. Global Onychomycosis (Tinea Unguium) Drug Manufacturers, Product Type & Application
- Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Onychomycosis (Tinea Unguium) Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
- Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
- Table 30. North America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 31. North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024) & (US$ Million)
- Table 32. North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030) & (US$ Million)
- Table 33. Europe Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 34. Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024) & (US$ Million)
- Table 35. Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030) & (US$ Million)
- Table 36. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 37. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024) & (US$ Million)
- Table 38. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030) & (US$ Million)
- Table 39. Latin America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 40. Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024) & (US$ Million)
- Table 41. Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030) & (US$ Million)
- Table 42. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 43. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2019-2024) & (US$ Million)
- Table 44. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2025-2030) & (US$ Million)
- Table 45. Pfizer Company Detail
- Table 46. Pfizer Business Overview
- Table 47. Pfizer Onychomycosis (Tinea Unguium) Drug Product
- Table 48. Pfizer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 49. Pfizer Recent Development
- Table 50. Yangtze River Company Detail
- Table 51. Yangtze River Business Overview
- Table 52. Yangtze River Onychomycosis (Tinea Unguium) Drug Product
- Table 53. Yangtze River Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 54. Yangtze River Recent Development
- Table 55. Torrent Pharma Company Detail
- Table 56. Torrent Pharma Business Overview
- Table 57. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product
- Table 58. Torrent Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 59. Torrent Pharma Recent Development
- Table 60. J&J Company Detail
- Table 61. J&J Business Overview
- Table 62. J&J Onychomycosis (Tinea Unguium) Drug Product
- Table 63. J&J Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 64. J&J Recent Development
- Table 65. Chengdu Brilliant Company Detail
- Table 66. Chengdu Brilliant Business Overview
- Table 67. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product
- Table 68. Chengdu Brilliant Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 69. Chengdu Brilliant Recent Development
- Table 70. Novartis Company Detail
- Table 71. Novartis Business Overview
- Table 72. Novartis Onychomycosis (Tinea Unguium) Drug Product
- Table 73. Novartis Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 74. Novartis Recent Development
- Table 75. Qilu Pharmaceutical Company Detail
- Table 76. Qilu Pharmaceutical Business Overview
- Table 77. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product
- Table 78. Qilu Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 79. Qilu Pharmaceutical Recent Development
- Table 80. Xiuzheng Pharmaceutical Company Detail
- Table 81. Xiuzheng Pharmaceutical Business Overview
- Table 82. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product
- Table 83. Xiuzheng Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 84. Xiuzheng Pharmaceutical Recent Development
- Table 85. Hubei Hengan Company Detail
- Table 86. Hubei Hengan Business Overview
- Table 87. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product
- Table 88. Hubei Hengan Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 89. Hubei Hengan Recent Development
- Table 90. TARO Company Detail
- Table 91. TARO Business Overview
- Table 92. TARO Onychomycosis (Tinea Unguium) Drug Product
- Table 93. TARO Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 94. TARO Recent Development
- Table 95. Perrigo Company Detail
- Table 96. Perrigo Business Overview
- Table 97. Perrigo Onychomycosis (Tinea Unguium) DrugProduct
- Table 98. Perrigo Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 99. Perrigo Recent Development
- Table 100. Galderma pharm Company Detail
- Table 101. Galderma pharm Business Overview
- Table 102. Galderma pharm Onychomycosis (Tinea Unguium) DrugProduct
- Table 103. Galderma pharm Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 104. Galderma pharm Recent Development
- Table 105. Zhejiang Deyer Company Detail
- Table 106. Zhejiang Deyer Business Overview
- Table 107. Zhejiang Deyer Onychomycosis (Tinea Unguium) DrugProduct
- Table 108. Zhejiang Deyer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 109. Zhejiang Deyer Recent Development
- Table 110. Valeant Pharma Company Detail
- Table 111. Valeant Pharma Business Overview
- Table 112. Valeant Pharma Onychomycosis (Tinea Unguium) DrugProduct
- Table 113. Valeant Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 114. Valeant Pharma Recent Development
- Table 115. Moberg Company Detail
- Table 116. Moberg Business Overview
- Table 117. Moberg Onychomycosis (Tinea Unguium) DrugProduct
- Table 118. Moberg Revenue in Onychomycosis (Tinea Unguium) Drug Business (2017-2022) & (US$ Million)
- Table 119. Moberg Recent Development
- Table 120. Pfizer Company Information
- Table 121. Pfizer Business Overview
- Table 122. Pfizer Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 123. Pfizer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 124. Pfizer Recent Development
- Table 125. Yangtze River Company Information
- Table 126. Yangtze River Business Overview
- Table 127. Yangtze River Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 128. Yangtze River Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 129. Yangtze River Recent Development
- Table 130. Torrent Pharma Company Information
- Table 131. Torrent Pharma Business Overview
- Table 132. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 133. Torrent Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 134. Torrent Pharma Recent Development
- Table 135. J&J Company Information
- Table 136. J&J Business Overview
- Table 137. J&J Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 138. J&J Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 139. J&J Recent Development
- Table 140. Chengdu Brilliant Company Information
- Table 141. Chengdu Brilliant Business Overview
- Table 142. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 143. Chengdu Brilliant Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 144. Chengdu Brilliant Recent Development
- Table 145. Novartis Company Information
- Table 146. Novartis Business Overview
- Table 147. Novartis Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 148. Novartis Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 149. Novartis Recent Development
- Table 150. Qilu Pharmaceutical Company Information
- Table 151. Qilu Pharmaceutical Business Overview
- Table 152. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 153. Qilu Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 154. Qilu Pharmaceutical Recent Development
- Table 155. Xiuzheng Pharmaceutical Company Information
- Table 156. Xiuzheng Pharmaceutical Business Overview
- Table 157. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 158. Xiuzheng Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 159. Xiuzheng Pharmaceutical Recent Development
- Table 160. Hubei Hengan Company Information
- Table 161. Hubei Hengan Business Overview
- Table 162. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 163. Hubei Hengan Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 164. Hubei Hengan Recent Development
- Table 165. TARO Company Information
- Table 166. TARO Business Overview
- Table 167. TARO Onychomycosis (Tinea Unguium) Drug Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 168. TARO Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 169. TARO Recent Development
- Table 170. Perrigo Company Information
- Table 171. Perrigo Business Overview
- Table 172. Perrigo Onychomycosis (Tinea Unguium) DrugRevenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 173. Perrigo Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 174. Perrigo Recent Development
- Table 175. Galderma pharm Company Information
- Table 176. Galderma pharm Business Overview
- Table 177. Galderma pharm Onychomycosis (Tinea Unguium) DrugRevenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 178. Galderma pharm Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 179. Galderma pharm Recent Development
- Table 180. Zhejiang Deyer Company Information
- Table 181. Zhejiang Deyer Business Overview
- Table 182. Zhejiang Deyer Onychomycosis (Tinea Unguium) DrugRevenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 183. Zhejiang Deyer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 184. Zhejiang Deyer Recent Development
- Table 185. Valeant Pharma Company Information
- Table 186. Valeant Pharma Business Overview
- Table 187. Valeant Pharma Onychomycosis (Tinea Unguium) DrugRevenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 188. Valeant Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
- Table 189. Valeant Pharma Recent Development
- Table 190. Moberg Company Information
- Table 191. Moberg Business Overview
- Table 192. Moberg Onychomycosis (Tinea Unguium) DrugRevenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million)
- Table 193. Moberg Revenue in Onychomycosis (Tinea Unguium) Drug Business (2019-2024) & (US$ Million) Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.